JPMorgan Chase & Co. Cuts Heartflow (NASDAQ:HTFL) Price Target to $35.00

Heartflow (NASDAQ:HTFL) had its price objective lowered by JPMorgan Chase & Co. from $40.00 to $35.00 in a research report released on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other equities research analysts have also recently issued reports on HTFL. Canaccord Genuity Group lifted their price objective on Heartflow from $40.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company reduced their target price on Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Heartflow currently has an average rating of “Moderate Buy” and an average target price of $37.67.

Heartflow Stock Up 0.5%

HTFL stock opened at $26.02 on Thursday. The stock has a market capitalization of $2.23 billion and a P/E ratio of -14.38. The firm has a 50-day simple moving average of $26.86 and a 200-day simple moving average of $30.41. Heartflow has a 52 week low of $20.13 and a 52 week high of $41.22.

Insider Buying and Selling at Heartflow

In other Heartflow news, insider Campbell Rogers sold 65,153 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $24.49, for a total value of $1,595,596.97. Following the transaction, the insider directly owned 76,034 shares of the company’s stock, valued at $1,862,072.66. This trade represents a 46.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John C.M. Farquhar sold 22,562 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the transaction, the chief executive officer owned 591,656 shares in the company, valued at approximately $16,246,873.76. This represents a 3.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 2,127,399 shares of company stock valued at $59,295,771.

Hedge Funds Weigh In On Heartflow

Institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd acquired a new position in Heartflow during the fourth quarter worth $27,000. TFC Financial Management Inc. acquired a new stake in shares of Heartflow in the 3rd quarter worth $40,000. Russell Investments Group Ltd. purchased a new position in shares of Heartflow during the 4th quarter worth $45,000. Legal & General Group Plc acquired a new position in shares of Heartflow during the 3rd quarter valued at about $59,000. Finally, Strs Ohio acquired a new position in shares of Heartflow during the 4th quarter valued at about $99,000.

Key Headlines Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong top‑line growth — HeartFlow reported revenue of $49.13M vs consensus $46.58M, up ~40.5% year‑over‑year, signaling accelerating adoption and top-line momentum. MarketBeat: Q4 results & transcript
• Positive Sentiment: Bullish analyst move — Canaccord raised its price target to $43 and maintained a Buy rating, implying a sizable upside and providing supportive institutional sentiment. Benzinga: Canaccord price target raise
• Neutral Sentiment: Analysts cut targets but stayed positive — JPMorgan lowered its PT from $40 to $35 but kept an Overweight rating, signaling confidence in the business even while trimming valuation assumptions. Benzinga: JPMorgan PT change
• Neutral Sentiment: Wells Fargo also trimmed its PT (from $38 to $35) but maintained an Overweight rating, another sign of cautious optimism. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Independent analysis available — Seeking Alpha published a piece reviewing HeartFlow’s strategy and growth opportunities; useful for investors analyzing the longer‑term thesis. Seeking Alpha: HeartFlow: Getting Into The Flow
• Negative Sentiment: EPS miss and continued losses — HeartFlow reported GAAP EPS of ($0.29) vs consensus ($0.16), missing estimates and underscoring margin pressure and ongoing unprofitability (PE remains negative). MarketBeat: EPS miss / earnings details
• Negative Sentiment: Valuation and trend considerations — Despite the rally, the stock remains below its 50‑day and 200‑day moving averages and carries a wide range of analyst targets, indicating continued volatility and mixed near‑term sentiment. Benzinga: HTFL earnings & estimates

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.